Clinical trial

Effects of MK7418 on Diuresis and Renal Function in Congestive Heart Failure Patients

NCT00652782

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention rolofyline Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Comparator Placebo (unspecified) Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Effects of MK7418 on Diuresis and Renal Function in Congestive Heart Failure Patients

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2004-12-01

PhasePHASE2

Conditions

Congestive Heart Failureverified · MONDO: congestive heart failure

Renal Impairmentunresolved

Interventions

rolofylineDRUG

Comparator Placebo (unspecified)DRUG

Sponsors & collaborators

NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)lead sponsor

Merck Sharp & Dohme LLCcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00652782 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.